Malaysia Diabetes Care Devices Market - Growth, Trends, and Forecasts (2022 - 2027)

The Malaysia Diabetes Care Devices Market is expected to register a CAGR greater than 5.1% over the forecast period, 2022-2027.

The Malaysian Ministry of Health announced that the Southeast Asian nation recorded 5,809 new COVID-19 cases in 24 hours, including 5,782 domestically infected and 27 imported ones, bringing the national tally to 2,541,147. So far, about 78.4 percent of the Malaysian population have received at least one dose of vaccine against COVID-19, while 75.9 percent have been fully vaccinated. Out of every 10 people who died from COVID-19 in Malaysia this year, about four of them had diabetes, the Health Ministry tells Sunday Star. In Malaysia, one in five people lives with diabetes which works out to about 3.9 million people aged 18 and above.

Young diabetics are on the rise. A higher number of younger people are getting diabetes, with the number of patients aged between 18 and 40 doubling over the past 15 years. The rising number of diabetics means an increased burden of the disease and its complications: heart disease, stroke, blindness, chronic kidney disease, and lower limb amputation, among others.

In fact, most of the coronavirus deaths in Malaysia have underlying comorbidities, with diabetes and hypertension topping the list.

Key Market Trends

Management Devices Hold Highest Market Share in Malaysia Diabetes Care Devices Market

Malaysia has the highest rate of diabetes in the Western Pacific region and one of the highest in the world and costing around 600 million US dollars per year. The rising trend is due to several factors, including population growth, population aging, urbanization, and rising obesity and physical inactivity rates. The rising incidence of diabetes and its consequences in Malaysia inspired this study to systematically identify, characterize, and estimate the pooled prevalence of diabetes and prediabetes in Malaysia. Although the use of insulin pumps in the West has increased by leaps and bounds, especially among type 1 diabetic individuals, its use in Malaysia remains very limited. The basal insulin infusion, which substitutes the intermediate- or long-acting subcutaneous insulin injection, provides insulin continuously throughout the day at pre-set rates that are changed based on the individual's specific requirements.

A community initiative supported by AstraZeneca in partnership with the Malaysian Endocrine & Metabolic Society (MEMS), The first-ever survey took place online from 12 April until 9 May 2021, with the support of several pharmacies and media partners. The purpose of this inaugural survey is to obtain a baseline of Malaysia's awareness level and also to identify key knowledge gaps. The insights from this year's 2,539 responses (which have been stratified to represent the overall population) will shape the way AstraZeneca and MEMS conceptualises public education initiatives in the year ahead.

The Goverenment intiatives driving the market in forecast period.

Increasing Diabetes Population in Malaysia

Because diabetes and prediabetes are on the rise in Malaysia, the Malaysian government implements diabetes prevention and control programs across the country. The Malaysian government should establish a comprehensive approach and plan to improve diabetes knowledge, control, prevention, and treatment to reduce the prevalence of diabetes in the country. Being overweight and obese are key drivers of the younger diabetes population in Malaysia. recent NHMS found that one in two adults in Malaysia is overweight or obese. Those with diabetes have high levels of glucose or sugar in their blood. It's a disease that is caused by the body not producing enough of the hormone insulin to control the amount of blood sugar. It can also be caused when the body doesn't use insulin efficiently, also known as insulin resistance. Factors that drive this process include obesity, unhealthy eating habits, sedentary lifestyles, and genetics. In Malaysia, current statistics from the ministry's National Diabetes Registry (NDR)show that 84% of patients with diabetes are overweight, and among them are young Malaysians aged 18 to 40. The ministry is currently looking into an initiative known as the Sama-Sama program, which aims to empower family members and caregivers to provide support for people living with diabetes to improve control and outcomes of the disease. "Under the program, the ministry is joining forces with the private sector to train healthcare providers and later, caregivers. The ministry is now investigating the Sama-Sama program, which aims to empower family members and caregivers to offer support for persons living with diabetes to enhance disease control and outcomes. The ministry is collaborating with the commercial sector on the program to train healthcare personnel and, subsequently, carers.

As a result, the diabetes care devices market in Malaysia is predicted to expand gradually in the coming years.

Competitive Landscape

The new technologies in diabetes devices, like continuous glucose monitoring, increased the market for monitoring devices. The mergers and acquisitions between the players, like the acquisition of TypeZero Technologies by Dexcom, are paving the way for automated insulin delivery. The acquisition has sent Dexcom ahead on its way in the race to create an artificial pancreas system, rather than merely offering a boost to the continuous glucose monitoring devices market.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support